Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

0

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On December5, 2017, Proteostasis Therapeutics, Inc.’s VP, Finance and Principal Accounting Officer, Brett Hagen, provided notice of his resignation from the Company, effective December31, 2017, for personal reasons.

(c) On December7, 2017, the Board of Directors of the Company elected Helen M. Boudreau, the Company’s Chief Financial Officer and Treasurer, as the Company’s Principal Accounting Officer.

Ms.Boudreau, age 51, has been our Chief Financial Officer and Treasurer since July 2017.Ms.Boudreau served on our Board of Directors from February 2016 to July 2017. Prior to joining the Company, Ms.Boudreau served as the Chief Financial Officer of FORMA Therapeutics, Inc. from 2014 to 2017. From 2008 to 2014, Ms.Boudreau worked at Novartis in a variety of senior roles, including Chief Financial Officer of Novartis Corporation, the U.S. corporate arm of Novartis AG (NYSE: NVS), Vice President of Investor Relations, and Vice President and Chief Financial Officer for Novartis Oncology, a global business unit. Before joining Novartis, Ms.Boudreau worked at Pfizer, Inc. (NYSE: PFE), where she served in multiple leadership positions, including Vice President of Finance, Customer Business Unit and Commercial Operations, VicePresident of Finance, Research and Development, and the Senior Director of Financial Planning and Strategic Analysis. Prior to Pfizer, Ms.Boudreau held strategic and operational roles at Yum Brands/PepsiCo., McKinsey& Company, and Bank of America. Ms.Boudreau received a B.A. in Economics from the University of Maryland and an M.B.A. from the Darden School at the University of Virginia.


About Proteostasis Therapeutics, Inc. (NASDAQ:PTI)

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.